IONS (IONS)

$72.97
-3.20%
$12.6B
Market Cap
P/E Ratio
0.38
Beta
Dividend Yield
Piotroski 4/9Altman Z 2.2 Gray ZoneBeneish M -2.70 CleanROIC−WACC -16.1%

Quantitative Summary

Deterministic

Financial health is average: Piotroski 4/9, Altman Z 2.2.

Generated deterministically from quant metrics and financial statements. Not a recommendation.

Algorithmic Teardown

AI-Generated

The fundamental economics of IONS present a stark dichotomy between aggressive top-line expansion and deteriorating capital efficiency. While revenue growth accelerates at 33.8% year-over-year, the company generates negative operating cash flows, evidenced by a net margin contraction to -40.4%. This profitability deterioration is compounded by an ROIC of -8.5%, which sits significantly below the weighted average cost of capital (WACC) of 7.1%, resulting in a deleterious spread of -15.6% that erodes shareholder value despite high gross margins near 98%. The DuPont decomposition suggests this weakness stems from margin compression rather than leverage or turnover issues, as indicated by the severe negative profitability factor score (RMW) of -0.910. Although the Altman Z-Score of 2.2 signals potential distress and the Piotroski F-Score of 4/9 reflects mediocre financial health, the Beneish M-Score of -2.70 indicates low likelihood of earnings manipulation; however, the negative ROIC-WACC spread fundamentally undermines long-term equity creation.

Valuation dynamics appear misaligned with the underlying capital destruction metrics. The market appears to be pricing in a high-growth narrative that ignores the current inability to convert sales into profit or return on invested capital. Given the -15.6% ROIC-WACC spread, any standard DCF model would imply significant overvaluation unless future margins expand dramatically and sustainably, challenging the implied growth assumptions currently embedded in the stock price. The disconnect between the robust revenue trajectory and the deep negative net margin suggests that current multiples may be detached from cash-flow generation capabilities, creating a scenario where valuation re-rating depends entirely on an operational turnaround rather than organic momentum.

Risk-adjusted performance metrics reveal conflicting signals regarding the stock's historical behavior versus its structural risks. The annual Fama-French Alpha of 29.92% suggests strong outperformance relative to traditional factor models over the past year, potentially driven by a distinct growth tilt (HML: -0.364). However, this alpha is counterbalanced by a severely negative profitability factor score (-0.910), indicating that recent returns are not supported by improving fundamental quality but rather by speculative positioning or temporary anomalies. Investors must weigh the historical momentum against the structural drag of negative capital allocation and weak profitability factors to determine if current prices reflect sustainable upside or impending mean reversion based on deteriorating fundamentals.

Generated by LLM from quantitative data inputs. May contain inaccuracies. Not investment advice.

Price Chart with Moving Averages

Loading chart...
SMA 50 SMA 200

Technical Setup

AI Generated

The current price action for IONS at $75.56 presents a neutral-to-bullish technical configuration that often attracts the attention of institutional capital seeking momentum plays. The alignment of short-term and long-term Simple Moving Averages suggests a structured uptrend, indicating that larger market participants may be accumulating positions as the asset consolidates above key support levels. This structural integrity typically signals confidence from sophisticated traders who utilize moving average crossovers to gauge trend direction without relying on high-frequency noise. Volume trends accompanying this price movement are critical for validating institutional intent; if trading volume has been expanding alongside price appreciation, it implies that significant capital is flowing into the asset rather than retail speculation alone driving the rally. Such synchronized behavior between price and volume often precedes sustained moves as institutions deploy larger orders to establish or add to their holdings without triggering excessive volatility. Conversely, any divergence where price rises on diminishing volume could suggest a lack of fresh institutional interest, potentially leading to stagnation until new capital enters the market. Ultimately, this setup reflects a phase where established trends are being tested by major players looking for optimal entry points within an appreciating asset class. The absence of bearish divergence or heavy selling pressure at these levels allows larger entities to maintain long positions while monitoring broader macroeconomic factors that could influence their allocation strategies further.

RSI (14)
SMA 50
SMA 200

Quant Health Deep Dive

4/9
Piotroski F-Score
Average — mixed operational signals
2.2
Altman Z-Score
Grey Zone — between 1.8 and 3.0 thresholds. Thresholds: >3 safe, 1.8–3 grey, <1.8 distress.
-2.70
Beneish M-Score
Below threshold — no statistical earnings quality concern per Beneish model. Threshold: <-2.22 = below threshold.

Profitability & Value Creation

98.3%
Gross Margin
-40.4%
Net Margin
-8.5%
ROIC
7.6%
WACC
ROIC − WACC Spread: -16.1%— Negative spread.
+33.8%
Revenue Growth (YoY)
+16.0%
Earnings Growth (YoY)
-325.7M
Free Cash Flow

Balance Sheet Health

6.20x
Debt / Equity
3.83x
Current Ratio
-3.5x
Interest Coverage
-2.43%
FCF Yield
-273.1M
EBITDA

Earnings Surprise History

Q4
✓ Beat
Est: $-1.03
Act: $-0.92
+10.4%
Q3
✓ Beat
Est: $0.16
Act: $0.85
+415.1%
Q2
✓ Beat
Est: $-1.05
Act: $-0.61
+41.8%
Q1
✓ Beat
Est: $-1.22
Act: $-1.15
+5.6%

EPS estimates vs actuals for the most recent reported quarters. Source: yfinance.

Risk Profile

42.6%
Annual Volatility
2.20
Sharpe (1Y)
0.65
Sharpe (3Y)
-52.4%
Max Drawdown (3Y)
-52.4%
Max Drawdown (5Y)

Sharpe = risk-adjusted return (higher is better). Max drawdown = largest peak-to-trough decline. 1,200+ trading days.

Underwater (Drawdown from Peak)

How far below the all-time high the price has been over time. Deeper = more pain for holders.

Loading drawdown chart...

Rolling 60-Day Beta vs S&P 500 (VOO)

How the stock's sensitivity to market moves changes over time. β > 1 = more volatile than the market.

Loading beta chart...
Rolling Beta Market (β = 1.0)

Fama-French 5-Factor Exposure

Academic factor model decomposition — what's really driving this stock's returns.

0.37
Market β
Mkt-RF
+0.522
Size (SMB)
Small-cap tilt
-0.364
Value (HML)
Growth tilt
-0.910
Profit (RMW)
Weak
+0.281
Invest (CMA)
Conservative
Alpha (annual): +29.92%
R²: 14.0%of variance explained by 5 factors

Fama-French 5-Factor Model. Data: Kenneth French Data Library. Regression over 3 years of daily returns.

Fundamentals

-123.0
Forward P/E
27.33
PEG Ratio
25.83
Price/Book
2M
Avg Volume
$86.74
52W High
$33.43
52W Low
74%
52W Range Position

Passive Flow Attribution

ETF Draft Effect
$686M
Tracked Passive Exposure
8
ETFs Holding IONS
0.18%
Avg Weight in ETFs
$380B
Total ETF AUM

When investors buy or sell ETFs like ARKG or XBI, the fund manager is mechanically forced to buy or sell IONS shares regardless of IONS's individual fundamentals. We estimate $686M of passive capital is structurally linked to IONS through 8 tracked ETFs. Passive flows have a limited but growing influence on IONS's daily trading dynamics.

Passive exposure = Σ (ETF AUM × stock weight in ETF) across 8 tracked ETFs. Actual passive ownership is larger (includes mutual funds). Not investment advice.

ETF Contagion Visualizer

Simulate a price drop in IONS to visualize passive redemption contagion across ETFs and collateral stocks.

IONS Shock
-0%
Est. Passive Redemption
$0
Systemic Risk
STABLE
IONSEpicenterVBETFVXFETFVONGETFLLYLow RiskTWSTLow RiskJNJLow RiskCRSPLow RiskTEMHigh Risk
IONS Price Drop (%)0

If IONS (IONS) experiences a significant drawdown, ETF redemptions can create collateral selling pressure on co-held stocks. Our model identifies Eli Lilly & Co. (LLY) as the most exposed collateral stock, sharing 2 ETFs with IONS. This is the "Passive Contagion" effect described in the Inelastic Market Hypothesis.

Contagion model based on shared ETF exposure and constituent weights across 9 tracked ETFs. Estimated selling pressure is a simplified model — actual impact depends on market liquidity, ETF redemption mechanics, and market-maker activity.

IONS Ownership Dynamics

Passive funds hold 1 in every 17 IONS shares, reducing daily market volatility.

Ticker
IONS
Total Shares
165M
ETF Lock-Up
6.0%
Display Mode
Total Float Impact
6.0%Locked Float

IONS (IONS) exerts measurable gravity on the passive index market, currently representing 1.7% of the ARK Genomic Revolution ETF (ARKG) and 1.2% of the XBI (XBI). Across 9 tracked ETFs, approximately 10M shares (6.0% of float) are held by passive funds and rarely trade on the open market. As passive ownership grows, index inclusion changes may increasingly drive price discovery.

Float lock-up computed from 9 ETFs tracked by SecuritiesDB. Actual passive ownership is higher (includes mutual funds, pension funds, etc.).

IONS Institutional Volume Profile

252-day volume distribution by price level. The Point of Control (POC) marks the price where the most institutional volume transacted — an implicit support/resistance floor.

TICKER
IONS
PRICE
$72.97
FLOOR (POC)
$74.75
STRENGTH
High
$35$37$40$4312%$45$48$51$53$56$59$61$64$67$69$7214%$72.97$75POC 15%$778%$8010%$839%$85
Focus Zone
Point of Control (POC) Support (below price) Resistance (above price) Current Price

The highest-volume price zone for IONS over the past year sits near $74.75 (15% of 252-day volume). The current price of $72.97 sits 2.4% below the POC — suggesting potential mean-reversion upside if institutional demand reasserts at this level. The highly concentrated volume profile (15% at POC) indicates strong consensus on fair value — institutional participants have repeatedly transacted near this price.

Volume Profile computed from 252 trading days of OHLCV data. Volume allocated to price bins proportionally based on daily high-low range. Not investment advice.

Fails-to-Deliver (FTD) History

SEC-reported settlement failures. Elevated FTDs can indicate high short-selling pressure, operational settlement issues, or naked shorting activity.

DateFailed SharesClose PriceNotional Value
2026-05-0773$76.85$5,610.05
2026-05-047,917$75.28$595,991.76
2026-04-171$75.26$75.26
2026-04-131,892$75.17$142,221.64
2026-04-1051$76.43$3,897.93
2026-04-07110$74.33$8,176.3
2026-04-061,056$74.79$78,978.24
2026-04-0261,032$75.13$4.6M
2026-03-314,940$72.52$358,248.8
2026-03-261$72.70$72.7
2026-03-256,847$69.68$477,098.96
2026-03-235$70.99$354.95
2026-03-20157$71.32$11,197.24
2026-03-1930,432$71.67$2.2M
2026-03-1795$72.34$6,872.3
2026-03-13755$72.34$54,616.7
2026-03-1210,219$74.79$764,279.01
2026-03-111,337$75.66$101,157.42
2026-03-1015,034$75.36$1.1M
2026-03-0471,539$78.66$5.6M
2026-03-0323,547$81.96$1.9M
2026-02-2534,535$85.45$3.0M
2026-02-2452,735$84.60$4.5M
2026-02-2319,581$83.15$1.6M
2026-02-1116,000$84.29$1.3M
2026-02-0686$83.48$7,179.28
2026-02-058,381$84.99$712,301.19
2026-02-03456$83.07$37,879.92
2026-01-2981$81.92$6,635.52
2026-01-233,066$81.79$250,768.14

Source: SEC Regulation SHO FTD data. Data is reported with a ~30 day delay. High FTD quantities relative to average daily volume may indicate settlement stress.

Price Correlations

Statistical correlation of daily returns with other stocks. High correlations indicate stocks that move together; negative correlations can offer diversification.

Peer252-Day (1Y)126-Day (6M)Direction
WTGXXNaNNaN
BEAM0.3240.427Moderate
MRK0.2970.394Low correlation
BMY0.2820.420Low correlation
AMGN0.2810.463Low correlation
INSM0.2800.359Low correlation
CRSP0.2780.390Low correlation
ULTA0.2720.185Low correlation
PFE0.2610.347Low correlation
ALNY0.2580.359Low correlation

Pearson correlation of daily log returns. 252d ≈ 1 trading year. Computed from price history. Not investment advice.

Compare IONS to Peers

Quant metrics computed deterministically from financial statements and price data. Updated: 2026-06-02.

SecuritiesDB provides programmatic data aggregation for informational purposes only. None of the metrics, summaries, or algorithmic flags constitute a recommendation to buy or sell any security.